Lupin Limited, a leading global pharmaceutical company headquartered in Mumbai, India, has announced that it has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Amifampridine Tablets, 10 mg. This approval marks a significant milestone for Lupin as it is one of the first ANDA applicants for this drug, making it eligible for 180 days of shared generic exclusivity in the U.S. market.
The Amifampridine Tablets, 10 mg, have been deemed bioequivalent to the reference listed drug, Firdapse® Tablets, 10 mg, produced by Catalyst Pharmaceuticals, Inc. This approval allows Lupin to market its generic version for the same indications as the reference drug, potentially expanding its footprint in the U.S. pharmaceutical market. The exclusivity period is a strategic advantage, enabling Lupin to capture a significant share of the market before other generic competitors enter.
Lupin Limited is renowned for its extensive portfolio, which includes generics, complex generics, specialty medicines, and biosimilars. The company’s strong presence in over 100 markets globally is supported by its robust manufacturing and research infrastructure, comprising 15 manufacturing facilities and six research centres. With a dedicated workforce of over 26,000 professionals, Lupin continues to lead in core therapeutic areas such as cardiovascular, respiratory, diabetes, gastrointestinal, and women’s health.
The approval of Amifampridine Tablets not only reinforces Lupin’s position in the U.S. market but also aligns with its strategy to expand its healthcare ecosystem through diagnostics, digital health, and patient-support programs. Analysts view this development as a positive step for Lupin, potentially boosting its revenue streams and strengthening its competitive edge in the pharmaceutical industry. As the company continues to focus on sustainability and innovation, the market will be keenly observing how Lupin leverages this exclusivity period to enhance its market presence.
